Showing 11,901 - 11,920 results of 84,632 for search '(( 50 ((nn decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( 2 c decrease ))', query time: 1.83s Refine Results
  1. 11901
  2. 11902

    <i>CBP/p300-Interacting Transactivator with Glu/Asp-Rich C-Terminal Domain 2</i> (CITED2) regulates GATA-2 expression in K562 cells. by Yo Saito (790757)

    Published 2015
    “…Actin was used as a loading control. (B,C) <i>GATA-2</i> mRNA expression and <i>GATA-2</i> 1S and 1G transcripts were significantly decreased (mean ± SE, n = 3, p < 0.001). * p<0.05.…”
  3. 11903
  4. 11904
  5. 11905
  6. 11906

    <i>C. trachomatis</i> L2 induces a biphasic activation of Erk1/2 which contributes to the induction of <i>fgf2</i> mRNA expression. by Jung Hwa Kim (43468)

    Published 2011
    “…Inhibition of either the early peak of Erk activation or the late peak of Erk activation decreased <i>C. trachomatis</i> L2 induction of <i>fgf2</i> mRNA but did not affect the distribution of FGF2 isoforms. …”
  7. 11907

    Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase by Safiatou T. Coulibaly (816058)

    Published 2015
    “…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”
  8. 11908
  9. 11909
  10. 11910
  11. 11911
  12. 11912
  13. 11913
  14. 11914

    The recruitment of Paf1C to the <i>frq</i> ORF is regulated by the WCC activity. by Mengmeng Zhou (9197699)

    Published 2025
    “…<p>(A) The enrichment of PAF-1 (Left) or RTF-1 (Right) at the <i>frq</i> ORF middle region significantly decreased in <i>wc-2</i><sup><i>KO</i></sup> strain at DD14. …”
  15. 11915
  16. 11916

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  17. 11917

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  18. 11918

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  19. 11919
  20. 11920